Influenza, Human  >>  ImmuFact (eftilagimod alpha)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ImmuFact (eftilagimod alpha) / Immutep
NCT00354263: Phase I Study of IMP321 Given Alone or as an Adjuvant to a Reference Flu Antigen

Completed
1
60
Europe
IMP321, hLAG-3Ig, CD223, LAG-3, saline
Immutep S.A.S., SGS Aster-Cephac (CRO)
Healthy
09/05
02/06

Download Options